Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE I OPEN-LABEL PHARMACOKINETICS AND SAFETY STUDY OF TALAZOPARIB (MDV3800) IN PATIENTS WITH ADVANCED SOLID TUMORS AND NORMAL OR VARYING DEGREES OF RENAL IMPAIRMENT

NCT02997163 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02997163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02997163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE I OPEN-LABEL PHARMACOKINETICS AND SAFETY STUDY OF TALAZOPARIB (MDV3800) IN PATIENTS WITH ADVANCED SOLID TUMORS AND NORMAL OR VARYING DEGREES OF RENAL IMPAIRMENT
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
February 21, 2017
Completion date
January 30, 2019
Enrollment
34 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors